Page last updated: 2024-09-03

vadimezan and paclitaxel

vadimezan has been researched along with paclitaxel in 9 studies

Compound Research Comparison

Studies
(vadimezan)
Trials
(vadimezan)
Recent Studies (post-2010)
(vadimezan)
Studies
(paclitaxel)
Trials
(paclitaxel)
Recent Studies (post-2010) (paclitaxel)
2721610131,8745,72915,395

Protein Interaction Comparison

ProteinTaxonomyvadimezan (IC50)paclitaxel (IC50)
Integrin beta-3Homo sapiens (human)0.034
Integrin alpha-V Homo sapiens (human)0.034
ATP-dependent translocase ABCB1Homo sapiens (human)2.598
Botulinum neurotoxin type A Clostridium botulinum5.2
UDP-glucuronosyltransferase 2B7Homo sapiens (human)4.9
UDP-glucuronosyltransferase 1-6Homo sapiens (human)4.9
Substance-K receptorHomo sapiens (human)6.125
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)4.9
UDP-glucuronosyltransferase 1A4Homo sapiens (human)4.9
UDP-glucuronosyltransferase 2B10 Homo sapiens (human)4.9
Delta-type opioid receptorHomo sapiens (human)4.202
Tyrosine-protein kinase MerHomo sapiens (human)4.9
Tubulin beta-3 chainHomo sapiens (human)0.0082
Beta-tubulin Leishmania donovani1
Nucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)7.9433
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)0.26
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)0.28

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's3 (33.33)29.6817
2010's5 (55.56)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Henricson, BE; Li, ZY; Manthey, CL; Perera, PY; Vogel, SN1
Lee, AE; McKeage, MJ; Pruijn, FB; Shalal-Zwain, S; Siim, BG; Wilson, WR1
Chouaid, C; Freitag, L; Gibbs, D; Jameson, MB; Lafitte, JJ; Mainwaring, PN; McKeage, MJ; Quoix, E; Reck, M; Rosenthal, MA; Serke, M; Sullivan, R; Von Pawel, J1
Freitag, L; Gibbs, D; Jameson, MB; Mainwaring, PN; McKeage, MJ; Reck, M; Rosenthal, MA; Sullivan, R; Von Pawel, J1
Hida, T; Hirashima, T; Horai, T; Horio, Y; Kobayashi, K; Nishio, M; Shi, MM; Tamiya, M; Tanii, H; Yamamoto, N1
Albert, I; Douillard, JY; Fan, X; Fandi, A; Heo, DS; Lara, PN; Losonczy, G; McKeage, MJ; Nakagawa, K; Reck, M; Scagliotti, G; von Pawel, J1
Cathomas, R; Erdmann, A; Früh, M; Fustier, P; Krasniqi, F; Küttel, E; Mamot, C; Pless, M; Rauch, D; Siano, M; Simcock, M; Tscherry, G; Zippelius, A1
Behe, M; Braun, F; Grosu, AL; Milanović, D; Niedermann, G; Weber, W1
Bertherat, J; Beuschlein, F; Frantsev, R; Hantel, C; Jäckel, C; Lira, R; Mussack, T; Ozimek, A; Ragazzon, B; Reincke, M1

Trials

5 trial(s) available for vadimezan and paclitaxel

ArticleYear
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
    British journal of cancer, 2008, Dec-16, Volume: 99, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome; Xanthones

2008
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2009, Volume: 65, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Xanthones

2009
Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.
    Cancer science, 2011, Volume: 102, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Tissue Distribution; Treatment Outcome; Xanthones

2011
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Aug-01, Volume: 29, Issue:22

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Paclitaxel; Quality of Life; Surveys and Questionnaires; Treatment Failure; Xanthones

2011
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).
    Clinical lung cancer, 2013, Volume: 14, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Treatment Outcome; Xanthones

2013

Other Studies

4 other study(ies) available for vadimezan and paclitaxel

ArticleYear
Dissection of LPS-induced signaling pathways in murine macrophages using LPS analogs, LPS mimetics, and agents unrelated to LPS.
    Progress in clinical and biological research, 1995, Volume: 392

    Topics: Animals; Antibodies, Monoclonal; Gene Expression Regulation; In Vitro Techniques; Lipid A; Lipopolysaccharide Receptors; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred C3H; Paclitaxel; Phosphoproteins; Signal Transduction; Xanthenes; Xanthones

1995
Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cancer chemotherapy and pharmacology, 2003, Volume: 51, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Carboplatin; Dose-Response Relationship, Drug; Drug Synergism; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Paclitaxel; Stilbenes; Time Factors; Xanthenes; Xanthones

2003
The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.
    BMC cancer, 2012, Jun-13, Volume: 12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Mice; Mice, Nude; Paclitaxel; Positron-Emission Tomography; Tumor Burden; Xanthones; Xenograft Model Antitumor Assays

2012
TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors.
    Molecular and cellular endocrinology, 2016, Mar-05, Volume: 423

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; DNA-Binding Proteins; Female; Humans; Interleukin-1 Receptor-Associated Kinases; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Mice, Nude; Nuclear Proteins; Paclitaxel; Proportional Hazards Models; Signal Transduction; Transcriptional Activation; Tumor Necrosis Factor alpha-Induced Protein 3; Tumor Necrosis Factor-alpha; Xanthones; Xenograft Model Antitumor Assays

2016